US-based biotech company Concerto Biosciences has entered into a development and commercialisation agreement with Sacco System.
The collaboration is aimed at advancing “next-generation” microbial ingredient discovery.
The partnership links Concerto, which focuses on microbial ecology, with Sacco System, a biotechnology group supplying solutions to the food, nutraceutical, pharmaceutical and agro-veterinary sectors.
Concerto CEO and co-founder Cheri Ackerman said: “This collaboration will set a new standard for microbe-based product innovation. Our platform is designed to generate massive datasets that provide empirical insight into how microbes function together. Partners like Sacco contribute deep domain expertise and commercial muscle.”
Under the deal, the two companies plan to create new ingredients made up of interacting microbial communities designed to deliver defined functional characteristics.
Sacco System will provide access to its portfolio of food-grade cultures alongside its applied expertise in food microbiology.
Concerto, in turn, will deploy its analytical platform to examine Sacco’s collection, using its kChip technology to build and measure millions of cocultures and its kAI model to process and interpret the resulting datasets.
The company said its platform is designed to support product development in several areas, including food science and nutrition, skin health, and women’s health.
Sacco scientific director Fabio Dal Bello added: “Our microbial collection represents decades of investment in food microbiology and captures the extensive biodiversity found across diverse food ecosystems worldwide. Each microorganism has been thoroughly characterised at phenotypic and genotypic levels; however, a substantial portion of their functional potential arises from microbial interactions within structured and dynamic communities.”
Last December, US-based microbial science company Grisso also unveiled a new precision probiotic range, describing the launch as part of its focus on clinically tested formulations.
It introduced three products built around its patented Weizmannia coagulans BC99 strain, which has been the subject of several clinical studies.
